

OUTCOMES IN RENAL TRANSPLANT RECIPIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTER EXPERIENCE



Ana Castro¹, Vanda Guardado¹, Jorge Malheiro¹, La Salette Martins¹, Manuela Almeida¹, Sofia Pedroso¹, Leonídio Dias¹, António Castro Henriques¹, António Cabrita¹

1- Oporto Hospital Center, Nephrology and Transplantation Department, Oporto, Portugal.



INTRODUCTION

Lupus Nephropathy (NL) continues to be a major cause of morbidity and mortality in patients with **Systemic Lupus Erythematosus (SLE)**. Although the prognosis of NL has improved considerably in recent years, end-stage renal disease (ESRD) develops in up to 10% of patients with SLE¹. **Renal transplantation (RT) is considered the treatment of choice for these patients.** However, the prognosis of renal transplant recipients with SLE remains controversial.

Aim: Evaluate kidney transplantation outcomes for patients with SLE at a single center.

METHODS


We retrospectively studied all SLE patients who received a kidney allograft in our center between July 2005 and 2016. For comparative purposes a **control group (No-SLE)** was selected, matched for recipient **age**, **female recipient**, **living donor**, **retransplant**, **year of transplant** and **peak PRA ≥5%**. Patient and allograft outcomes were compared between cases and controls.

RESULTS

There were **1190 kidney transplants** performed between **July 2005-2016**, including **17 in SLE patients [mean age 42.6 (31-51) years]**. **Mean follow-up** after renal transplantation was **4.3 (1.4-7.6) years**. In table 1 characteristics and outcomes in SLE and No-SLE kidney recipients are presented. From the Cox analysis performed, **SLE was the single independent predictor of graft failure (HR=8.93; P=0.041)**. **Early graft loss (<1 month after transplantation) was observed in 6 (35,3%) SLE patients, 5 due to intravascular thrombotic events and 1 due to a not functioning kidney.** Late graft loss occurred in 1 SLE patient due to chronic rejection. **SLE was significantly associated with shortened kidney graft survival, with 43.4 % of SLE grafts failing at 5 years, in contrast with only 5.9 % No-SLE.**

	No SLE N=17	SLE N=17	P
Recipient age (years), median (IQR)	36 (29-48.0)	42.6 (31-51)	0.734
Donor age (years), mean±SD	47 (39-56)	39 (24-55)	0.315
Female recipient, n (%)	16 (94)	16 (94)	1
Female donor, n (%)	5 (29)	5 (29)	1
Living donor, n (%)	6 (35)	6 (35)	1
Retransplant, n (%)	2 (12)	1 (6)	1
Year of transplant, median (IQR)	2009 (2007-2011)	2010 (2007-2013)	0.375
Dialysis vintage (years), median (IQR)	4.2 (0.7-7.6)	4.1 (0.7-6.0)	0.643
CKD etiology, n			-
SLE		17	
GN chronic	11		
ADPKD	2		
Unknown	4		
HLA mismatch, mean±SD	4.00±1.26	4.06±1.48	0.669
Peak PRA ≥5%, n (%)	4 (24)	4 (24)	1
Induction, n (%)			0.270
None	15 (88)	11 (65)	
Basiliximab	1 (6)	3 (18)	
ATG			
DGF, n (%)	3 (18)	1 (6)	0.603
AR, n (%)	3 (18)	3 (18)	1
Graft failure, n (%)	1 (6)	7 (41)	0.039
Patient death, n (%)	0	0	1

Table 1: Characteristics and outcomes in SLE and No-SLE kidney recipients.



CONCLUSIONS

In our study, SLE kidney recipient patients had a significantly shortened kidney graft survival. The risk for thrombotic complications was greater among SLE patients due to the high number of thrombotic complications observed shortly after transplant.

Identifier/Topic: Renal transplantation. Epidemiology and outcome.

Bibliography:

1- Cairolí E., Sanchez-Marcos C., Espinosa G. et al, Renal transplantation in systemic lupus erythematosus: outcome and prognostic factors in 50 cases from a single centre. Biomed Res Int. 2014;2014:746192.

